Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In Q1

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices go down. When compared to a stock’s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the RSI is below 30, according to Benzinga Pro.

Here's the latest list of major oversold players in this sector, having an RSI near or below 30.

Gossamer Bio Inc (NASDAQ:GOSS)

• On Feb. 23, the company announced topline results for the PROSERA Phase 3 Study of seralutinib in patients with PAH. “While we are disappointed to have narrowly missed the stringent prespecified statistical threshold for our primary endpoint, the result still clears the traditional 0.05 p-value, and we believe these data clearly demonstrate seralutinib is an active drug in patients with PAH,” said Faheem Hasnain, Chairman, Co-Founder, and CEO of Gossamer Bio. The company's stock fell around 76% over the past month and has a 52-week low of $0.33.
• RSI Value: 26.3
• GOSS Price Action: Shares of Gossamer Bio gained 23.4% to close at $0.58 on Wednesday.
• Benzinga Pro’s charting tool helped identify the trend in GOSS stock.

Brainsway Ltd – ADR (NASDAQ:BWAY)          

• On March 4, BrainsWay disclosed new clinical data showing a significantly faster, noninvasive way to treat depression without compromising the efficacy of one of psychiatry’s most impactful treatments. The company's stock has a 52-week low of $3.92.
• RSI Value: 19.1
• BWAY Price Action: Shares of Brainsway gained 7.4% to close at $12.45 on Wednesday.
• Edge Stock Ratings: 95.47 Momentum score with Value at 26.26.

Definitive Healthcare Corp (NASDAQ:DH)

• On Feb. 26, Definitive Healthcare posted in-line earnings for the fourth quarter. “Our fourth quarter results were at or above the high end of our guidance ranges on both the top and bottom line, demonstrating the meaningful progress we have made across our strategic pillars throughout 2025,” said Kevin Coop, CEO of Definitive Healthcare. “As we enter 2026, we are focused on continuing to improve retention rates and increase our upsell and cross-sell activity. We remain confident that we are taking the right steps to deliver improved operational and financial performance over time.” The company's stock fell around 38% over the past month and has a 52-week low of $1.07.
• RSI Value: 28.1
• DH Price Action: Shares of Definitive Healthcare gained 5.2% to close at $1.22 on Wednesday.
• Benzinga Pro’s signals feature notified of a potential breakout in DH shares.

Curious about other BZ Edge Rankings? Click here to discover how similar stocks measure up.

Photo via Shutterstock